What biomarker testing is recommended for metastatic Breast Cancer

Biomarker Testing for Metastatic Breast Cancer

Based on NCCN Guidelines for Patients: Metastatic Breast Cancer, here's what you should know about the biomarker testing recommended for your situation:

Why Biomarker Testing Matters

Biomarker testing looks at your specific tumor to identify unique characteristics that guide treatment decisions. As the NCCN Guidelines explain, "Because of biomarkers, a treatment that helps one person might not help you." This testing is crucial for metastatic breast cancer because it helps your oncology team select the most effective therapies for YOUR cancer specifically.

Standard Biomarker Tests (Always Recommended)

Your care team will test for these foundational biomarkers:

Hormone Receptors:

• Estrogen Receptor (ER) - determines if your cancer cells respond to estrogen
• Progesterone Receptor (PR) - determines if your cancer cells respond to progesterone
• Together, these are called HR status (hormone receptor status)

HER2 Status:

• Tests for HER2 protein, which affects treatment options significantly

These three tests form the basis of treatment planning for all metastatic breast cancer patients.

Additional Tumor Mutation Testing

According to NCCN Guidelines, your doctor may recommend testing for specific DNA mutations in your tumor cells. These mutations can be targeted with specific therapies:

• PIK3CA mutations - can be targeted with specific therapies
• ESR1 mutations - tested in hormone receptor-positive tumors
• AKT1 mutations - can guide treatment selection
• PTEN mutations - may influence treatment approach
• NTRK gene fusions - rare, but if present, drugs like larotrectinib (Vitrakvi) or entrectinib (Rozlytrek) may be options
• RET gene fusions - if present, selpercatinib (Retevmo) may be considered

Testing Methods Used

Your tumor sample may be tested using several approaches:

• Next-generation sequencing (NGS) - tests multiple genes at once
• FISH or ISH - specialized imaging techniques
• IHC (Immunohistochemistry) - protein detection method
• PCR (Polymerase chain reaction) - can detect very small amounts of abnormal DNA

Tumor Markers (Blood Tests)

Your doctor may also check blood tests for tumor markers like:

• CA 15-3
• CA 27.29
• CEA (carcinoembryonic antigen)

Important note: According to NCCN Guidelines, "not everyone has elevated levels of these markers and tumor markers alone are not a reliable method of detecting breast cancer. Therefore, they are not routinely checked and depend on your individual situation."

Liquid Biopsy Option

If your tumor tissue sample is limited, your doctor may recommend a liquid biopsy - a blood test that looks for circulating tumor DNA (ctDNA). This can sometimes identify mutations without needing more tissue.

Genetic Testing (BRCA1/2)

The NCCN Guidelines recommend that all patients with metastatic breast cancer should have germline BRCA1/2 testing (unless already done recently). This tests whether you inherited a genetic mutation that affects treatment options and has implications for your family.

---

Questions to Ask Your Oncology Team

1. Which biomarker tests have been done on my tumor, and what were the results?
2. Are there any additional biomarker tests you recommend for my specific situation?
3. How will these biomarker results affect my treatment options?
4. If my tumor sample is limited, would a liquid biopsy be helpful?
5. Have I been tested for BRCA1/2 mutations, and if not, do you recommend this?

---

Key Takeaway

Biomarker testing is essential for metastatic breast cancer because it reveals the specific characteristics of YOUR cancer. This information directly influences which treatments your doctor will recommend. Make sure you understand your results and ask your care team to explain what each finding means for your treatment plan.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.